View conference programme - The British Society for Rheumatology

51 UNDERSTANDING NON-RESPONSE TO INFLIXIMAB IN RHEUMATOID ARTHRITIS:
PREDICTING SUBSEQUENT OUTCOME.
MH Buch, Y Seto, SJ Bingham, V Bejarano, D Bryer, J White, P Emery. Academic Unit of Musculoskeletal
Disease, University of Leeds, Leeds, West Yorkshire, United Kingdom
52 AGGRESSIVE THERAPY WITH CONVENTIONAL DISEASE MODIFYING ANTI-RHEUMATIC
DRUGS (DMARD) DOES NOT PREVENT DISEASE PROGRESSION IN PATIENTS WITH STABLE
ESTABLISHED RHEUMATOID ARTHRITIS (RA): RESULTS OF A RANDOMISED OBSERVER-BLINDED
CONTROLLED CLINICAL TRIAL.
M Davis 1 , K Tricker 2 , C Roberts 3 , P Dawes 4 , A Hassell 4 , S Knight 5 , D Mulherin 6 , DL Scott 7 , D Symmons 2,5 .
1
Royal Cornwall NHS Trust, Truro, United Kingdom; 2 ARC Epidemiology Unit, University of Manchester,
Manchester, United Kingdom; 3 Biostatistics Group, University of Manchester, Manchester, United
Kingdom; 4 University Hospital of North Staffordshire NHS Trust, Stoke on Trent, United Kingdom; 5 East
Cheshire NHS Trust, Macclesfield, United Kingdom; 6 Mid-Staffordshire General Hospitals NHS Trust,
Cannock, United Kingdom; 7 King’s College Hospital, London, United Kingdom
53 ADDING LIGNOCAINE DOES NOT AFFECT SHORT OR MEDIUM-TERM OUTCOME IN
INTRA-ARTICULAR STEROID INJECTIONS.
C Rao, M Bukhari. Department of Rheumatology, Royal Lancaster Infirmary, Lancaster, Lancashire,
United Kingdom
54 RANDOMISED PLACEBO-CONTROLLED TRIAL OF INTRAMUSCULAR (IM) DEPOT
METHYLPREDNISOLONE IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS.
EH Choy 1 , GH Kingsley 1 , B Khoshaba 1 , N Pipitone 1 , L Dolan 2 , P Pitt 3 , B Dasgupta 4 , GS Panayi 1 , DL Scott 1 .
1
Academic Department of Rheumatology, GKT School of Medicine, London, United Kingdom;
2
Rheumatology, Queen Elizabeth Hospital, Greenwich, United Kingdom; 3 Rheumatology, Farnborough
Hospital, Farnborough, United Kingdom; 4 Rheumatology, Southend Hospital, Southend, United Kingdom
55 IS IT POSSIBLE TO PREDICT WHICH PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
WILL DERIVE RHEUMATOLOGICAL BENEFIT FROM STATIN THERAPY?
DW McCarey, N Sattar, R Hampson, R Madhok, IB McInnes, HA Capell. Centre for Rheumatic Diseases,
Royal Infirmary, Glasgow, United Kingdom
56 COMBINATION VS MONOTHERAPY FOR POOR PROGNOSIS RHEUMATOID ARTHRITIS:
A LONG-TERM FOLLOW-UP STUDY.
V Bejarano, C Philip, G Michael, K Heather, E Paul. Academic Unit of Musculoskeletal Disease, University
of Leeds, Leeds, United Kingdom
57 SYSTEMATIC REVIEW OF EFFECTIVENESS OF FIVE STRATEGIES TO PREVENT NSAID-INDUCED
GASTROINTESTINAL TOXICITY.
L Hooper 1 , TJ Brown 1 , RA Elliott 2 , K Payne 3 , C Roberts 4 , D Symmons 5 . 1
Cochrane Oral Health Group,
University of Manchester, Manchester, United Kingdom; 2 School of Pharmacy, Manchester University,
Manchester, United Kingdom; 3 Health Economics at Manchester, St Mary’s Hospital, Manchester, United
Kingdom; 4 School of Epidemiology and Health Sciences, Manchester University, Manchester, United
Kingdom; 5 ARC Epidemiology Unit, Manchester University, Manchester, United Kingdom
58 DEMOGRAPHIC TRENDS IN 5 COHORTS OF RHEUMATOID ARTHRITIS (RA) PATIENTS ENROLLED
IN PROSPECTIVE DISEASE MODIFYING ANTI-RHEUMATIC DRUG (DMARD) STUDIES 1986-2003.
S Irvine 1 , G Roberts 1 , R Madhok 1 , DR Porter 2 , JA Hunter 2 , IB McInnes 1 , HA Capell 1 . 1
Centre for Rheumatic
Diseases, Royal Infirmary, Glasgow, United Kingdom; 2 Rheumatology Department, Gartnavel General
Hospital, Glasgow, United Kingdom
59 EFFECT OF GENDER ON DISEASE-MODIFYING ANTI-RHEUMATIC DRUG (DMARD) PRESCRIPTION
IN RHEUMATOID ARTHRITIS (RA).
E Morrison 1 , R Hampson 2 , A Tierney 2 , L MacKenzie 2 , HA Capell 2 . 1
Rheumatology, Southern General
Hospital, Glasgow, United Kingdom; 2 Centre for Rheumatic Diseases, Royal Infirmary, Glasgow,
United Kingdom
40